博俊科技(300926.SZ)公告称，公司于近日收到中国证监会出具的《关于同意江苏博俊工业科技股份有 限公司向特定对象发行股票注册的批复》，同意公司向特定对象发行股票的注册申请。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000545 证券简称：金浦钛业 公告编号：2025－039 金浦钛业股份有限公司 2、股东大会召集人：公司董事会 公司已于2025年4月28日公告了股东大会召开通知。2025年4月29日，直接持有公司25.81%股份的控股 股东金浦集团提出临时提案并书面提交股东大会召集人。 根据《公司法》和《公司章程》的相关规定，单独或者合计持有公司3%以上股份的股东，可以在股东 大会召开10日前提出临时提案并书面提交召集人；召集人应当在收到提案后2日内通知其他股东，并将 该临时提案提交股东大会审议。经公司董事会核查，截至本公告披露日，公司控股股东金浦集团直接持 有公司股份254,700,000股，占公司总股本的25.81%，该提案人的身份符合相关规定，其提案内容未超 出相关法律法规和《公司章程》的规定及股东大会职权范围，且议案提交的程序符合《公司法》《深圳 证券交易所股票上市规则》《公司章程》和《股东大会议事规则》的相关规定，故公司董事会同意将上 述临时议案提交公司2024年年度股东大会审议。股东大会召集人按照《深圳证券交易所上市公司自律监 管指引第1号一主板上 ...

Group 1 - The company has announced adjustments to its plan for issuing shares to specific investors, reducing the total amount of funds to be raised from 204.54 million yuan to 203.37 million yuan [9][10][19] - The net proceeds from the share issuance will be used entirely for investment projects, with provisions for the use of self-owned or other funds prior to the arrival of the raised funds [9][10][19] - The company has emphasized that the adjustments made to the share issuance plan do not affect other aspects of the plan [8][17][19] Group 2 - The company held board meetings to approve the revised share issuance plan and related documents, with unanimous support from board members [14][17][46] - The company has committed to ensuring the authenticity and completeness of the financial reports and announcements made [2][13][42] - The company plans to hold an investor briefing on May 14, 2025, to discuss the 2024 annual results and the first quarter of 2025, allowing for interactive communication with investors [52][53][55] Group 3 - The company has outlined the necessity and rationale for the share issuance, stating it aligns with industry trends and future development needs, aiming to optimize capital structure and enhance financial strength [31][34] - The investment projects funded by the share issuance are consistent with the company's current business operations, aiming to strengthen market competitiveness [31][34] - The company has established a dedicated team to ensure the successful implementation of the investment projects, highlighting its commitment to effective management and operational efficiency [32][34][36] Group 4 - The company has conducted financial assessments to analyze the impact of the share issuance on key financial metrics, indicating a potential dilution of immediate returns for existing shareholders [28][29] - Measures have been proposed to mitigate the dilution of immediate returns, including improving operational efficiency and adhering to a strict cash dividend policy [35][38][39] - The company has received commitments from its directors and controlling shareholders to ensure the fulfillment of measures aimed at compensating for any dilution of returns [39][41]

登录新浪财经APP 搜索【信披】查看更多考评等级 ■ 注：上述表格中的2023年度及2022年度财务数据经郑郑会计师事务所有限公司审计。 三、关联交易主要内容和定价政策 公司与关联方发生的日常关联交易属于正常经营业务往来，主要包括伺服系统、织机电控配套部件、材 料、IC产品以及租赁办公场所和仓库等。具体合同由交易双方根据实际发生情况在预计金额范围内签 署。 公司日常关联交易的价格按照同类业务的市场价格并经交易双方平等协商确定，定价公允、合理，不存 在损害公司及其股东特别是中小股东利益的情形，不会对公司的独立性、经营成果和财务状况产生负面 影响，不会导致公司对关联方形成依赖。 四、关联交易目的和对上市公司的影响 公司日常关联交易是基于公司正常经营需要，关联方为公司的参股公司或实际控制人控制的企业，根据 各方资源优势合理配置，交易金额占同类业务比例较小。交易定价按照同类业务的市场价格并经交易双 方平等协商确定，遵守公平、公正的市场原则，不会损害公司及全体股东利益，不会对公司的独立性、 经营成果和财务状况产生负面影响，公司的主要业务、收入及利润不会对关联方形成依赖。 特此公告。 福建睿能科技股份有限公司董事会 20 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 东吴证券股份有限公司（以下简称"东吴证券"或"保荐人"）作为河南明泰铝业股份有限公司（以下简 称"明泰铝业"、"公司"或"发行人"）2023年向特定对象发行股票（以下简称"本次发行"）的保荐人，根 据《证券发行上市保荐业务管理办法》《上海证券交易所上市公司自律监管指引第11号一一持续督导》 等有关法律、法规的相关规定，负责明泰铝业的持续督导工作，持续督导期间为本次发行结束当年的剩 余时间及其后1个完整会计年度。截至2024年12月31日，持续督导期已届满。 （一）尽职推荐工作 按照相关法律法规要求，保荐人及保荐代表人对发行人情况进行尽职调查，组织编制申请文件并出具推 荐文件；提交推荐文件后，主动配合证监会、证券交易所的审核，组织公司及其它中介机构对证监会、 证券交易所的意见进行答复，按照证监会、证券交易所的要求对涉及本次证券发行上市的特定事项进行 尽职调查或核查，并进行专业沟通，按照证券交易所上市规则的要求提交推荐股票上市要求的相关文 件，并报中国证监会备案。 （二）持续督导工作 东吴证券根据《证券发行上市保荐业务管理办法》《上海证券交易所上市公司自律监管指引 ...

Core Viewpoint - The company, Hongchang Electronics, reported a decline in both revenue and net profit for 2024, primarily due to poor performance in its epoxy resin business, which has been significantly impacted by a challenging external environment and weak downstream demand [1][4]. Financial Performance - The total operating revenue for 2024 was 2.144 billion yuan, a year-on-year decrease of 4.29% [1][4]. - The net profit attributable to shareholders was 50.61 million yuan, down 41.59% year-on-year [1][4]. - The non-recurring net profit was 42.49 million yuan, reflecting a decline of 47.06% compared to the previous year [1]. Business Segment Performance - The epoxy resin business generated a net profit of 28.83 million yuan, showing a significant year-on-year decline [4]. - The production and sales volumes of epoxy resin were 97,100 tons and 97,500 tons, respectively, with decreases of 1.72% and 1.45% year-on-year [4]. - The copper-clad laminate and semi-cured sheet businesses performed relatively well, with increases in production and sales, but could not offset the negative impact from the epoxy resin segment [4]. Market Challenges - The company cited a complex international political and economic environment, slow global economic recovery, and multiple challenges in domestic economic operations as factors leading to weak market demand for epoxy resin and copper-clad laminates [4]. - Weak terminal consumption has adversely affected product gross margins and profitability [4]. Fundraising and Investment - To address market challenges, the company is actively pursuing a private placement of shares, having issued 249 million shares in September 2023, raising a total of 1.168 billion yuan, with a net amount of 1.154 billion yuan after expenses [5]. - The raised funds will primarily be allocated to the Zhuhai Hongchang Phase II project, which aims to produce 140,000 tons of liquid epoxy resin annually, and the Zhuhai Hongchang Phase III project, targeting 80,000 tons of electronic-grade functional epoxy resin [5][6]. Research and Development - Despite market challenges, the company continues to invest in R&D, particularly in high-frequency and high-speed resin and copper-clad laminate materials [7]. - New products, including a next-generation polyether formulation resin and halogen-free phosphorus-containing polyether resin, have passed customer evaluations and are making progress in the ultra-5G resin sector [7]. - The company has acquired a 67GHz PNA network analyzer to meet the electrical testing requirements for the latest products from Intel and AMD, and has made advancements in high-frequency materials for Nvidia platforms [7].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600498 证券简称：烽火通信 公告编号：2025-010 转债代码：110062 转债简称：烽火转债 烽火通信科技股份有限公司 关于2024年度向特定对象发行A股股票预案及 相关文件修订情况说明的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 烽火通信科技股份有限公司（以下简称"公司"）于2024年10月11日召开的第九届董事会第三次临时会议 和第九届监事会第一次临时会议、于2024年12月27日召开2024年第四次临时股东大会，审议通过了关于 公司2024年度向特定对象发行A股股票（以下简称"本次发行"）的相关议案。 2025年4 月21日，公司召开第九届董事会第七次临时会议、第九届监事会第四次临时会议，审议通过了 关于调整公司2024年度向特定对象发行A股股票的相关议案。本次发行方案的调整及相关文件的修订在 股东大会授权范围内（具体内容详见上海证券交易所网站www.sse.com.cn公告），无需提交股东大会审 议。相关文件主要修订情况如下： 一、 ...

Group 1 - The company has a 4.59% stake in Hangyuan Solar Thermal and has significant influence over it through board representation [1] - The company has established fair pricing policies for related party transactions based on market conditions [1][2] - Daily related party transactions are normal business activities that help the company meet customer needs and reduce costs [3] Group 2 - The company plans to accept a guarantee of up to RMB 570 million from related parties for financing in 2025, with no fees charged for the guarantee [7][9] - The independent directors have approved the related party transactions, confirming they do not harm shareholder interests [4][11] - The company has not incurred any losses from related party transactions and maintains its operational independence [3][4] Group 3 - The company intends to apply for a bank credit facility of up to RMB 570 million for 2025, subject to approval from the banks [12][13] - The actual financing amount will depend on the bank's approval and the company's operational needs [13] Group 4 - The company plans to use idle funds for entrusted wealth management, with an investment limit of up to RMB 300 million [16][19] - The investment aims to enhance the efficiency of idle funds while ensuring daily operational needs are met [16][19] Group 5 - The company has changed its accounting policies in accordance with new regulations issued by the Ministry of Finance, effective January 1, 2024 [23][28] - The changes are not expected to significantly impact the company's financial status or shareholder interests [28][29] Group 6 - The company has announced an online performance briefing for the 2024 annual report, scheduled for April 17, 2025 [33][35] - The briefing aims to facilitate communication with investors and gather feedback [33][36] Group 7 - The company has proposed to appoint a new auditing firm, Grant Thornton, for the 2025 fiscal year, pending shareholder approval [38][39] - The firm has extensive experience and qualifications in auditing listed companies [39][41] Group 8 - The company plans to issue shares to specific investors through a simplified process, with a total financing amount not exceeding RMB 300 million [49][51] - The issuance will be subject to shareholder approval and regulatory compliance [49][51]

Core Viewpoint - Dajia Weikang has decided to terminate its plan for a private placement of shares and withdraw the application due to the current capital market environment and after thorough communication and analysis among relevant parties [1][4]. Group 1: Termination of Share Issuance - The company held meetings on April 3 to approve the termination of the private placement of shares and the withdrawal of the application [1]. - The planned issuance was intended to raise up to 120 million yuan, with a share price of 7.45 yuan per share, and a maximum of 16,107,382 shares to be issued [1]. - The funds were to be used to supplement working capital after deducting issuance costs [1]. Group 2: Shareholder Information - The intended recipient of the shares was Wang Yiqing, a controlling shareholder and chairman of the company, who was to sign a conditional share subscription agreement [2]. - Wang Yiqing directly holds 70,144,219 shares and indirectly controls an additional 9,800,000 shares, totaling 79,944,219 shares, which is 38.92% of the company's total equity [2]. - Together with his spouse, they control 39.60% of the voting rights in the company [2]. Group 3: Previous Fundraising Efforts - Dajia Weikang was listed on the Shenzhen Stock Exchange on December 7, 2021, raising 639 million yuan, with a net amount of 569 million yuan after expenses [3]. - The funds from the initial public offering were intended for chain pharmacy expansion, smart logistics center projects, and repaying bank loans [3]. - The company had previously announced the termination of a simplified procedure for a private placement in 2022, which aimed to raise up to 199.12 million yuan for acquisitions and working capital [5].

Core Viewpoint - The company plans to issue A-shares to specific investors in 2025, which may dilute immediate returns for existing shareholders, but it has proposed measures to compensate for this dilution and ensure the protection of minority investors' rights [2][6][10]. Financial Impact Analysis - The company estimates a net profit range of -195 million to -157 million yuan for 2024, with a potential 50% increase in losses compared to 2024 [3][4]. - Three scenarios for 2025 net profit projections are analyzed: a 50% increase in losses, maintaining 2024 levels, and a 50% reduction in losses [4][5]. - The projected basic and diluted earnings per share (EPS) under these scenarios range from -0.90 to -1.36 yuan [4][5]. Necessity and Reasonableness of the Issuance - The issuance aligns with relevant policies and the company's strategic development plan, indicating its necessity and feasibility [6][7]. Use of Raised Funds - The raised funds will be allocated to "innovative drug R&D," "industrialization of traditional Chinese medicine," and "supplementing working capital," supporting the company's transition from generic drugs to innovative drugs and health consumption sectors [7][8][9]. Company’s Preparedness for Investment Projects - The company has accumulated significant experience and technical barriers in the liver health and antiviral sectors, with a strong talent pool and ongoing patent applications for its drug candidates [9]. Measures to Mitigate Dilution of Immediate Returns - The company will enhance its competitive advantages and profitability, actively implement fundraising projects, and strengthen fund management to mitigate the dilution of immediate returns for shareholders [10][11][12]. Commitments from Key Stakeholders - The company's board and senior management have committed to fulfilling the proposed compensation measures for shareholders, ensuring no unfair benefit is provided to other entities [14][15].